期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 20, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/ijms20051142
关键词
glucocorticoids; regulatory T (Treg) cells; peripherally derived Treg (pTreg) cells; thymus-derived Treg cells (tTreg); Treg cell number modulation; human autoimmune diseases; human allergic diseases; desensitizing treatment; tolerogenic response
资金
- Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [2015ZT9MXY_001]
- Fondo di Ateneo per la ricerca di base 2015
Glucocorticoids (GCs) are widely used to treat several diseases because of their powerful anti-inflammatory and immunomodulatory effects on immune cells and non-lymphoid tissues. The effects of GCs on T cells are the most relevant in this regard. In this review, we analyze how GCs modulate the survival, maturation, and differentiation of regulatory T (Treg) cell subsets into both murine models and humans. In this way, GCs change the Treg cell number with an impact on the mid-term and long-term efficacy of GC treatment. In vitro studies suggest that the GC-dependent expansion of Treg cells is relevant when they are activated. In agreement with this observation, the GC treatment of patients with established autoimmune, allergic, or (auto)inflammatory diseases causes an expansion of Treg cells. An exception to this appears to be the local GC treatment of psoriatic lesions. Moreover, the effects on Treg number in patients with multiple sclerosis are uncertain. The effects of GCs on Treg cell number in healthy/diseased subjects treated with or exposed to allergens/antigens appear to be context-dependent. Considering the relevance of this effect in the maturation of the immune system (tolerogenic response to antigens), the success of vaccination (including desensitization), and the tolerance to xenografts, the findings must be considered when planning GC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据